4 results
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
in HF and CKD. ... in HF and CKD. ... in HFrEF on GDMT ... visualabstract #table ... #CVD #CKD
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... -4 inhibitors SGLT2 ... Improved outcomes in CKD ... #medications #table
Stages in the development of HF and recommended therapy by stage. ACEI indicates angiotensin-converting enzyme inhibitor;
development of HF ... angiotensin-receptor blocker; CAD ... resynchronization therapy; DM, diabetes ... ejection fraction; GDMT ... #CHF #Congestive
Characteristics of Common Lipid Disorders
Polygenic hypercholesterolemia
Atherogenic dyslipidemia
 • Frequently accompanied by central obesity or diabetes
Familial hypercholesterolemia,
history of premature CHD ... history of premature CHD ... individuals exhibit CHD ... Family history of CHD ... Family history, CHD